Vigeo Therapeutics
PrivateLast Round
Series C
Mar 10, 2021
Total Funding Raised
$62.58M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Vigeo Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series C round in March 2021.
Vigeo Therapeutics is a biotechnology company that develops novel therapeutics for the treatment of cancer and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vigeo Therapeutics Comparables
Compare Vigeo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sapience Therapeutics | 80% | |
| Bexion Pharmaceuticals | 78% | |
| Imvax | 77% |
For institutional investors. Book with your work email.
Vigeo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 10, 2021 | ||||
| Series B | Dec 19, 2018 | ||||
| Series A | Nov 15, 2017 | ||||
| Series A | Jun 12, 2015 |
For institutional investors. Book with your work email.
Vigeo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Morningside Ventures | Series A, Series B |
| Morningside Group | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 9, 180% of current headcount.
- Mar 25, 2021
Raised $8 million in debt financing.
For institutional investors. Book with your work email.
Vigeo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vigeo Therapeutics's valuation, stock price, and market status.
Is Vigeo Therapeutics a public or private company?
Vigeo Therapeutics is a private company.
What is the current stock price of Vigeo Therapeutics?
Vigeo Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vigeo Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vigeo Therapeutics worth (valuation)?
Valuation information for Vigeo Therapeutics is not publicly available.
Can I buy Vigeo Therapeutics stock?
Vigeo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vigeo Therapeutics's last funding round?
Vigeo Therapeutics's most recent funding round was Series C on March 10, 2021.
Who are the main investors in Vigeo Therapeutics?
Key investors in Vigeo Therapeutics include Morningside Ventures, Morningside Group.
Will Vigeo Therapeutics IPO soon?
No public IPO plans have been announced for Vigeo Therapeutics.
How can I track Vigeo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vigeo Therapeutics's shares on secondary markets.